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At clinically relevant doses, chemotherapeutic SN1 DNA
methylating agents induce an ATR-mediated checkpoint re-
sponse in human cells that is dependent on functional MutS
and MutL. Deficiency of either mismatch repair activity ren-
ders cells highly resistant to this class of drug, but the mecha-
nisms linking mismatch repair to checkpoint activation have
remained elusive. In this studywe have systematically examined
the interactions of human MutS and MutL with proteins of
theATR-Chk1pathwayusing bothnuclear extracts andpurified
proteins. Using nuclear co-immunoprecipitation, we have
detected interaction ofMutS with ATR, TopBP1, Claspin, and
Chk1 and interaction of MutL with TopBP1 and Claspin. We
were unable to detect interaction of MutS or MutL with
Rad17, Rad9, or replication protein A in the extract system. Use
of purified proteins confirmed direct interaction ofMutS with
ATR, TopBP1, and Chk1 and of MutL with TopBP1. MutS-
Claspin and MutL-Claspin interactions were not demonstra-
ble with purified proteins, suggesting that extract interactions
are indirect or depend on post-translational modification. Use
of a modified chromatin immunoprecipitation assay showed
that proliferating cell nuclear antigen, ATR, TopBP1, and Chk1
are recruited to chromatin in a MutL- and MutS-dependent
fashion after N-methyl-N-nitro-N-nitrosoguanidine treatment.
However, chromatin enrichment of replication protein A,
Claspin, Rad17-RFC, and Rad9-Rad1-Hus1 was not detected
in these experiments. Although our failure to observe enrich-
ment of the latter activities could be due to sensitivity limita-
tions, these observations may indicate a novel mechanism for
ATR activation.
Mismatch repair is a mutation avoidance mechanism that
corrects DNA replication errors, inhibits recombination be-
tween quasi-homologous DNA sequences, and participates in
the early steps of checkpoint and apoptotic responses to several
types of DNA damage (reviewed in Refs. 1–4). Inactivation
of the human pathway elevates spontaneous mutability, renders
cells resistant to certain DNA damaging agents, causes typical
and atypical hereditary nonpolyposis colon cancer, and has
been implicated in the development of some sporadic tumors.
The most thoroughly studied function of mismatch repair
has been its role in replication fidelity. Although the eukaryotic
signals that direct repair of DNA biosynthetic errors to the
newly synthesized DNA strand have not been identified, a
strand-specific nick or gap is sufficient to direct the reaction in
mammalian cell extracts (5–7) and in several purified systems
(8–11). Analysis of these purified systems has indicated that
repair initiation involves activation of a latent endonuclease
activity of MutL (MLH1PMS2) in a reaction that requires a
mismatch, MutS (MSH2MSH6), replication factor C (RFC),2
proliferative cell nuclear antigen (PCNA), and ATP (12, 13).
Incision by MutL endonuclease is directed to the heterodu-
plex strand that contains a pre-existing break, yielding mole-
cules that contain strand discontinuities to either side of the
mismatch. These endonucleolytic products serve as substrates
for MutS-activated exonuclease I, which loads at a strand
break located 5 to the mispair and hydrolyzes a DNA segment
spanning the mismatch (8, 12). The ensuing gap is filled by
replication proteinA (RPA) and repaired byDNApolymerase 
in a reaction that also depends on PCNA and RFC (8, 10, 11, 14,
15). Covalent continuity is restored to the repaired strand by
the action of a DNA ligase (10).
In addition to their role in replication fidelity, MutS and
MutL function is required for normal checkpoint and apopto-
tic responses that occur upon exposure to SN1 DNA methyla-
tors, and cells deficient in these activities are highly resistant to
killing by these drugs (reviewed in Refs. 1 and 16–18). SN1
methylators, including temozolomide, procarbazine, decarba-
zine, N-methyl-N-nitrosourea, and N-methyl-N-nitro-N-ni-
trosoguanidine (MNNG), produce several classes of DNA
lesion, but O6-methylguanine (MeG) is largely responsible for
the cytotoxicity of the agents (19, 20). MeG is repaired by
O6-methylguanine-DNA methyltransferase (MGMT) (18) and
pairs with C or T during replication bypass, resulting MeG-C
and MeG-T mispairs (21). Although both mismatches activate
the repair system, MeG-T is a superior substrate (22–24). The
checkpoint response induced by clinically relevant doses of SN1
methylators occurs in the G2 phase of the second cell cycle (25)
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and appears to be regulated through the ATR-Chk1 pathway
with MutS and MutL acting upstream of ATR (22, 26–29).
Two models, which are not mutually exclusive, have been
proposed to explain the nature of MutS- and MutL-depen-
dent damage signaling in response to MeG lesions. The futile
repairmodel invokesmismatch-provoked excision triggered by
MeG mispairs at the replication fork. Because the damaged
guanine base resides on the template strand and repair targets
new DNA, activation of the repair system under these condi-
tions would lead to abortive turnover of the daughter strand,
ultimately triggering checkpoint activation (19). The alternate
direct signaling model suggests that recruitment of MutS and
MutL and perhaps other activities toMeG lesions is sufficient
to trigger activation of damage signaling and apoptotic path-
ways (30). Evidence consistent with both models is available.
The finding that SN1 methylator-induced checkpoint activa-
tion occurs during the second G2 is consistent with the futile
repair model, which requires replication pastMeG damage (19,
26, 31). Indeed, MeG-dependent abortive turnover that is de-
pendent on a functional mismatch repair system has been doc-
umented in nuclear extracts of mammalian cells (24), and in
vitro repair synthesis on DNAs containing MeG can lead to
persistent single-stranded breaks (24, 32). Electron micro-
scopic analysis has revealed mismatch repair-dependent accu-
mulation of single-stranded DNA gaps in newly replicated
DNA inMNNG-treated cells (31), and ATR-dependent check-
point activation in such cells is accompanied by formation of
nuclear foci that containATR andRPA, suggesting recruitment
of ATR to single-stranded DNA regions (26). Furthermore,
exonuclease 1, which participates in the excision step of mam-
malian mismatch repair, has been implicated in the cytotoxic
effects of 6-thioguanine and SN1 DNA alkylators (33, 34).
Although these findings are consistent with a futile repair
mechanism, compelling evidence for the direct signalingmodel
is also available. Yoshioka et al. (28) have demonstratedMutS-
and MutL-dependent ATR activation in mammalian cell
extracts using MeG-containing DNAs that are not expected to
support mismatch-provoked excision. Additional evidence for
such a mechanism has been provided by a mouseMsh6 separa-
tion of function mutation that confers a defect in mismatch
repair but retains sensitivity to killing by MNNG (35).
MutS andMutL are believed to act upstream of the ATR-
Chk1 checkpoint pathway in the damage response elicited by
MeG. According to current views, ATR-mediated signaling is
activated by replication interference or by lesions that stall rep-
lication forks, whereas theATM-Chk2 pathway is activated pri-
marily in response to double-stranded breaks (36). Activation
of the ATR-dependent pathway is believed to involve recruit-
ment of ATR-ATRIP, Rad17-RFC, and Rad9-Rad1-Hus1
(9-1-1) to sites of damage or replication fork stress (37), with
efficient activation of the system also dependent on TopBP1
andClaspin (38–40). Activated ATR phosphorylates a range of
substrates including the Chk1 kinase, which in turn regulates
downstream targets such as Cdc25A, Cdc25C, and p53, to
inhibit cell cycle progression (36).
Previous studies using co-immunoprecipitation from cell
extracts have suggested that MutS may be capable of interac-
tion with ATR and Chk1 (28, 29, 41), although these experi-
ments suffer from the caveat that the interactions observed
could be indirect, mediated by other molecular partners. How-
ever, the use of purified proteins has demonstrated thatMSH2,
in the absence of its MSH6 or MSH3 partners, can directly
interact with ATR (29). In an effort to better understand the
interplay between mismatch repair and DNA damage check-
points, we have systematically analyzed interactions between
MutS and MutL with components of the ATR-Chk1 check-
point pathway in nuclear extracts, in purified systems, and on
chromatin from cells that have been subjected to SN1 methyla-
tor damage.
EXPERIMENTAL PROCEDURES
Cell Culture and Reagents—Human lymphoblastoid B-cell
lines TK6 and MT1 (19) were grown in RPMI 1640 medium
supplemented with 10% (v/v) fetal bovine serum (HyClone).
HeLa S3 cells were cultured in RPMI 1640 medium supple-
mented with 5% fetal bovine serum. The 293T L cell line was a
gift from Josef Jiricny (University of Zurich) andwas cultured as
described (42). The cell line was derived from MLH1- and
MGMT-deficient human embryonic kidney 293T cells and
contains a stably integrated hMLH1 cDNA minigene that is
controlled by the Tet-Off expression system. To turn offMLH1
expression in these cells, 50 ng/ml doxycycline (Clontech) was
added into the medium every second day. MNNG (Sigma) was
dissolved in Me2SO immediately prior to use.
Nuclear Co-immunoprecipitation—Nuclear extracts were
prepared at 0–4 °C from TK6 cells and HeLa S3 cells as
described (5)with the followingmodifications. The nuclear pel-
lets were resuspended in 25 mM Hepes-KOH, pH 7.5, 450 mM
NaCl, 5 mM MgCl2, 0.1 mM EDTA. 0.15% Triton X-100 (v/v)
and then rotated on a ROTO-TORQUE rotator (Cole-Parmer)
for 30 min. The samples were centrifuged at 15,000  g for 20
min, and the supernatant was diluted 3-fold by adding two vol-
umes of 25 mM Hepes-KOH, pH 7.5, 5 mM MgCl2, and 0.1 mM
EDTA. Protein concentrations of the resulting nuclear extracts
were determined by Bradford assay, and the extracts were used
immediately.
For co-immunoprecipitation, 1 mg of nuclear extract was
incubated with 5 g of primary antibody overnight at 4 °C with
rotation. The antibodies used were control mouse IgG (Santa
Cruz Biotechnology), control rabbit IgG (Santa Cruz Biotech-
nology), and those directed against MSH6 (BD Biosciences),
PMS2 (BD Biosciences), ATR (Santa Cruz Biotechnology),
Rad17 (Santa Cruz Biotechnology), Rad9 (Bethyl Laboratories),
TopBP1 (Bethyl Laboratories), Claspin (GeneTex), and Chk1
(SantaCruz Biotechnology). Fiftyl of agarose-proteinGbeads
(50% slurry; Invitrogen) pre-equilibrated with wash buffer (25
mM Hepes-KOH, pH 7.5, 150 mM NaCl, 5 mM MgCl2, 0.1 mM
EDTA, 50 g/ml bovine serum albumin, 0.05% Triton X-100)
were then added, and the reactions were rotated at 4 °C for 1 h.
The beads were washed three times with wash buffer, resus-
pended in 30 l of 2 Laemmli SDS buffer (43), and the sam-
ples were subjected to SDS-PAGE and Western blotting.
Purified Protein-Protein Interactions—Preparation of the
purified proteins used in this study are described in the supple-
mental materials.
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All of the reactions were carried out at 0 4 °C. MutS or
MutL (final concentration, 20 nM) was incubated with 20 nM
checkpoint proteins in 500 l of binding buffer (25 mM Hepes-
KOH, pH 7.5, 150mMNaCl, 5mMMgCl2, 0.1mM EDTA, 0.02–
0.1% Triton X-100, 50 g/ml bovine serum albumin, 0.1%
phenylmethylsulfonyl fluoride, 1 mM dithiothreitol, and prote-
ase inhibitor mixture; Roche Applied Science). After rotation
for 2 h, 5 g of antibody (mouse IgG, anti-MSH2, anti-MSH6,
anti-PMS2, or anti-MLH1) was added, and the rotation contin-
ued for 1 h. Fifty l of agarose-protein G beads, pre-equili-
brated with binding buffer, were added, and the reactions were
rotated for 1 h more. The beads were then washed twice with
binding buffer, resuspended in Laemmli buffer, and analyzed as
described above.
ForGST-tagged proteins (GST-Chk1 andGST-TopBP1) and
FLAG-tagged proteins (FLAG-ATR and FLAG-Claspin), tag
pull-down assays were also performed. Purified tagged proteins
(20 nM in 500 l of binding buffer) were incubated with 50 l of
glutathione-Sepharose beads (GE Healthcare) or anti-FLAG
M2 affinity gel (Sigma) for 1 h, followed by two washes with
binding buffer.MutS orMutL (20 nM) was then added. After
2 h of incubation, the beads were washed with binding buffer
and resuspended in Laemmli SDS buffer as described above.
Modified ChIP Assay—TK6 cells, MT1 cells, and 293T L
cells (cultured with or without doxycycline) were treated with
0.2 M MNNG and harvested at 0, 6, 12, 24, 48, and 72 h post-
treatment (zero time sampleswere removed just beforeMNNG
addition). Cross-linking and chromatin preparation were per-
formed by a modification of the procedure of Fousteri et al.
(44). Briefly, the cells were treatedwith 0.5% formaldehyde for 5
min at room temperature, followed by the addition of 0.125 M
glycine to quench unreacted formaldehyde. All of the subse-
quent steps were performed at 0° 4 °C, and all of the buffers
contained 0.1 mM EDTA, 0.5 mM EGTA, 1 mM dithiothreitol,
and protease inhibitors (0.1% phenylmethylsulfonyl fluoride
(saturated in isopropanol), 1g/ml leupeptin, 1g/ml E-64, 0.5
g/ml aprotinin, and 5 g/ml pepstatin A). The cells (1  108)
were washed with phosphate-buffered saline (pH 7.4) and lysed
for 10minwith rotation in 10ml of 50mMHepes-KOH, pH 7.8,
150 mM NaCl, 0.5% Nonidet P-40, 0.25% Triton X-100, 10%
(v/v) glycerol. After centrifugation (4,000 g, 5 min), the pellet
was resuspended in 10 ml of 10 mM Tris-HCl, pH 8.0, 200 mM
NaCl, rotated 10min, and centrifuged at 15,000  g for 10min.
The chromatin pellet was resuspended in 1 ml of 50 mM Tris-
HCl, pH 7.9, 5 mM CaCl2 and digested with 500 units of micro-
coccal nuclease (New England Biolabs) at 37 °C for 10 min.
After the addition of EGTA to 10 mM, the samples were centri-
fuged at 15,000  g for 20 min, and the supernatant containing
cross-linked chromatin was used for measurement of DNA
concentration and ChIP assays.
To determine DNA content, 50 l of chromatin solution
were added to 159l of 0.25MNaCl, 62g/ml RNaseA (Sigma)
and incubated for 4 h at 65 °C. Two l of proteinase K (10
mg/ml; Thermo Fisher Scientific) were added, and the solu-
tions were incubated at 42 °C for 1.5 h. DNA was isolated by
phenol/chloroform extraction and ethanol precipitation, and
concentration was determined by absorbance at 260 nm. DNA
fragment size (weight average size of about 400 bp; mode about
200 bp) was checked by agarose gel electrophoresis.
ForChIP reactions, digested chromatin sampleswere diluted
with radioimmune precipitation assay buffer (10 mM Tris-HCl,
pH 8.0, 140 mM NaCl, 1% Triton X-100, 0.1% sodium deoxy-
cholate, 0.1% SDS) to 0.5 mg/ml DNA. The diluted samples (1
ml) were immunoprecipitated overnight with 5 g of anti-
MSH6, anti-MLH1, or control mouse IgG. Fifty l of agarose-
protein G beads, pre-equilibrated with radioimmune precipita-
tion assay buffer supplemented with 50 g/ml bovine serum
albumin and 1 mg/ml sonicated calf thymus DNA, were then
added, and the reactions were rotated at 4 °C for 1 h. The beads
were washed three times with radioimmune precipitation assay
buffer and resuspended in 30l of 2Laemmli SDS buffer. The
samples were heated at 95 °C for 30 min to reverse cross-links
prior to SDS-PAGE and Western blotting.
Western Blotting—Western blot was done as previously
described (45). The primary antibodies used were specific for
MSH6 and MSH2 (Santa Cruz Biotechnology); PMS2 and
MLH1 (Santa Cruz Biotechnology); ATR, Rad17, and Rad9
(Bethyl Laboratories); RPA70, TopBP1, Claspin, Chk1, and
-actin (Novus); poly(ADP-ribose) polymerase-1 (Alexis Bio-
chemicals); and histone H3 (Millipore). Secondary antibodies
were anti-mouse or rabbit or goat IgGs conjugated with horse-
radish peroxidase (Invitrogen). The protein bands were visual-
ized using the ECLWestern blotting system (GE Healthcare).
RESULTS
Nuclear Co-immunoprecipitation—Co-immunoprecipita-
tion from cell extracts has indicated that MutS may interact
with ATR and Chk1 (28, 29, 41), but indirect interactions were
not excluded in these studies. In addition, the use of purified
proteins has indicated that ATR is capable of direct interaction
with the MSH2 polypeptide (29), although the latter protein is
not known to display biological activity in the absence of its
MSH6 or MSH3 partners (46). Here we used both nuclear
extracts and purified proteins to systematically examine inter-
actions of MutS and MutL with components of the ATR-
Chk1 pathway. For nuclear co-immunoprecipitation, HeLa
cells and TK6 cells were used, both of which are proficient in
mismatch repair and display MutS- and MutL-dependent
checkpoint responses to SN1 methylators (22, 26, 28, 31).
As shown in Fig. 1A (left panel), ATR, TopBP1, Claspin, and
Chk1 were co-immunoprecipitated from HeLa and TK6
nuclear extracts by antibodies against the MSH6 subunit of
MutS, indicating direct or indirect interactions between
MutS and these checkpoint activities. Despite the use of sev-
eral anti-MSH6 antibodies directed against different epitopes,
Rad17, Rad9, and RPA were not detected in MSH6 immuno-
precipitates. When MutL was immunoprecipitated by PMS2
antibody, TopBP1, and Claspin were co-immunoprecipitated
(Fig. 1A, right panel), but other checkpoint activities were not
detected.
Interaction of ATR, TopBP1, Claspin, and Chk1 withMutS
and the interaction of TopBP1 and Claspin with MutL were
confirmed by reciprocal nuclear co-immunoprecipitation
using antibodies specific for the checkpoint proteins (Fig. 1B). It
is noteworthy that in contrast to input samples, theMSH2 sub-
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unit of MutS was preferentially recovered when co-immuno-
precipitated with antibodies directed against TopBP1 or Chk1
(Fig. 1B). This may indicate preferential interaction of these
activities with MSH2 and dissociation of MutS subunits dur-
ing precipitation.
Interaction ofMutS andMutLwith Checkpoint Proteins in
a Purified System—We employed purified proteins to further
clarify the nature of these interactions. With the exception of
FLAG-ATR and FLAG-Claspin, both of which were 80%
pure, the proteins used in these experiments were essentially
homogeneous (supplemental Fig. S1). When bound to anti-
FLAGM2affinity beads, FLAG-ATR can pull downMSH6 (Fig.
2A), indicating direct interaction of ATR with MutS. How-
ever, interaction between ATR and MutL was not detected
(Fig. 2A, right panel). Consistent with these observations, we
have found that immunoprecipitation of MutS co-precipi-
tates FLAG-ATR, but immunoprecipitation ofMutL does not
(data not shown). This is in agreement with nuclear extract
results described above and the previous finding of Wang and
Qin (29). Similar experiments (Fig. 2, B–G) demonstrated that
MutS interacts directly with Chk1 and TopBP1, but we have
been unable to detect MutS interaction with 9-1-1, Rad17-
RFC, RPA, or FLAG-Claspin using pulldown methods. These
experiments also demonstrated robust interaction of MutL
with GST-TopBP1, but MutL interaction with other check-
point proteins was not detected. Interaction of MutS with
GST-Chk1 and GST-TopBP1 and interaction of MutL with
GST-TopBP1 were confirmed by reciprocal pulldowns using
anti-MSH6 or anti-MLH1, respectively (data not shown).
Association ofMutSandMutLwithCheckpoint Proteins in
Vivo—To evaluate interactions of these proteins in cells upon
SN1 methylator treatment, we employed formaldehyde cross-
linking in a modified ChIP assay to capture interacting multi-
protein-DNA assemblies in vivo (44, 47). Two pairs of mis-
match repair proficient/deficient cell lines were used: 293T L
cells, cultured with or without doxycycline, and TK6 and MT1
cells. 293T L cells culturedwithout doxycycline (referred to as
293T L cells) express MLH1, are mismatch repair-profi-
cient, and display a G2/M checkpoint response to SN1 methy-
lators, whereas cells cultured in the presence of 50 ng/ml doxy-
cycline (referred to as 293T L cells) shut off MLH1
expression and are defective in mismatch repair and the check-
point response to SN1 methylators (26, 42). TK6 andMT1 cells
are human lymphoblastoid cells with MGMT deficiency. The
MT1 cell line was derived fromTK6 by single-step selection for
high level DNAmethylator resistance and is deficient inMutS
due of missense mutations in both alleles ofMSH6 (19, 30, 48).
The four cell lines were treated with 0.2 M MNNG and
harvested at 0, 6, 12, 24, 48, and 72 h post-treatment, andDNA-
bound protein complexes were cross-linked with formalde-
hyde. Chromatin fractions were obtained after removal of cyto-
plasm and soluble nuclear fractions by detergent extraction,
which was confirmed by Western blotting using antibodies
against marker proteins (supplemental Fig. S2). Chromatin was
digested to an average DNA fragment size of about 400 bp with
microccoal nuclease, and chromatin-associated MutS (in
293T L and 293T L cells) or MutL (in TK6 and MT1
cells) immunoprecipitated using anti-MSH6 or anti-MLH1,
respectively. Proteins present in immunoprecipitateswere then
analyzed by SDS-PAGE and Western blot after cross-link
reversal.
The results of anti-MSH6 immunoprecipitation of equiva-
lent amounts of chromatin fragments (0.50 mg DNA) derived
from 293T L and 293 L cells are shown in Fig. 3 and
presented in quantitative form in Fig. 4. As can be seen, a num-
ber of activities co-immunoprecipitated withMSH6 in the zero
time formaldehyde cross-linked chromatin sample, including
MSH2, MLH1, PCNA, ATR, TopBP1, and Chk1 (Fig. 3).
Because this sample was removed prior to MNNG treatment,
these findings indicate significant association of these repair
and checkpoint activities withMSH6-enriched chromatin frac-
tions that have not been subjected to exogenous alkylator dam-
age. The possibility of chromatin enrichment of repair and
checkpoint activities was evaluated by normalizing Western
blot signals for each protein of interest to that for histone H3 in
the sample (Fig. 4). This analysis revealed a transient 1.7–1.8-
FIGURE 1. Reciprocal nuclear co-immunoprecipitation. A, immunoprecipi-
tation from nuclear extracts of HeLa or TK6 cells was done using anti-MSH6 or
anti-PMS2 antibodies as described under “Experimental Procedures.” The
lanes marked as Input (1/20) indicate that 1⁄20 of total extract was loaded.
Mouse IgG was used as a control for MSH6 or PMS2 antibody. The labels on
the left indicate proteins co-precipitating with MSH6 or PMS2 as judged by
Western blot after SDS-PAGE. Although some ATR signal is evident in the IgG
control lane, quantitation of Western results demonstrated that the ATR sig-
nal in anti-MSH6 immunoprecipitates is 3– 4-fold higher than that in the con-
trol sample. B, co-immunoprecipitation from nuclear extracts of TK6 cells was
done by using antibodies against the checkpoint proteins indicated at the top
of the figure. MutS and MutL in immunoprecipitates were evaluated after
SDS-PAGE using antibodies directed against MSH2 and MSH6 (upper panel) or
MLH1 and PMS2 (lower panel).
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fold increase in chromatin-associated MutS that was evident
in 6- and 12-h post-treatment samples from293TL cells but
not observedwith chromatin from293TL cells. The enrich-
ment of MutS in 293T L chromatin was accompanied by
increases in chromatin-bound MLH1, with both repair activi-
ties returning to basal levels by 24 h. PCNA, ATR, TopBP1, and
Chk1 were also subjected to transient elevation inMSH6-asso-
ciated chromatin fractions, but with a delay relative to chroma-
tin enrichment ofMutS andMLH1. Thus, elevation of PCNA,
ATR, TopBP1, and Chk1 levels was
initially observed in 12-h chromatin
samples and persisted to 24 h,
returning to near basal levels by
48 h. In contrast to these results
obtained with chromatin isolates
obtained from 293T L cells, no
significant variation of chromatin
association of MutS or the latter
set of activitieswas observed in sam-
ples obtained from 293 L cells
(Figs. 3 and 4B), implying that these
effects areMLH1-dependent. Inter-
estingly, the basal association of
TopBP1 observed in anti-MSH6
zero time chromatin precipitates
from 293T L cells was not
observed in otherwise identical
samples from 293T L cells (Fig.
3), suggesting that this association is
also MLH1-dependent.
Similar results were obtained in
comparative studies with TK6 and
MT1 cells, which are MSH6-profi-
cient and -deficient, respectively,
when cross-linked chromatin frag-
ments were precipitated with anti-
MLH1. However, in this case the
basal chromatin association of
PCNA, ATR, TopBP1, and Chk1 in
zero time samples was much
reduced as compared with those
obtained with 293T cells (Fig. 5).
Because of the reduced levels of
basal association, the variation in
chromatin association of mismatch
repair and checkpoint activities was
particularly evident in samples from
TK6 cells. As observed with 293T
L cells, chromatin enrichment of
MutL and MSH6 was observed in
chromatin samples isolated 6 and
12 h after MNNG exposure of TK6
cells, with enrichment for PCNA,
ATR, TopBP1, and Chk1 demon-
strable only in 12- and 24-h post-
exposure isolates. No detectable
enrichment for any of these proteins
was observed in chromatin samples
obtained fromMSH6-deficient MT1 cells.
It is noteworthy that although we have demonstrated
MutS-, MutL-, and damage-dependent chromatin associa-
tion of PCNA,ATR,TopBP1, andChk1,we have been unable to
demonstrate chromatin enrichment of several other activities
that are expected to be involved in signaling via the ATR-Chk1
pathway. In particular enrichment of RPA, Rad17, Rad9, or
Claspin was not observed in chromatin fractions obtained by
precipitation with anti-MSH6 or anti-MLH1 in two different
FIGURE 2. Interactions of MutS or MutL with purified checkpoint proteins. A, MutS or MutL was
incubated with FLAG-ATR as described under “Experimental Procedures.” Anti-FLAG M2 affinity gel was used
to pull down FLAG-ATR and its interacting proteins. Incubation with FLAG peptide (20 nM) was used as a control
for FLAG-ATR. ATR, MSH6, and MLH1 in the precipitates were determined by Western blot after SDS-PAGE.
B, 9-1-1 was incubated alone, or with MutS or MutL followed by pulldown with anti-MSH2 or anti-PMS2
bound to protein G beads (“Experimental Procedures”). RAD9, MSH2, and PMS2 in the precipitates were deter-
mined by Western blot after SDS-PAGE. C, procedure was as in B, except RPA was used instead of 9-1-1, and
RPA70 was probed in the Western blot. D, procedure was as in A except that glutathione-Sepharose beads were
used to pull down GST-TopBP1 and its interacting partners. GST was used as a negative control for GST-TopBP1.
E, procedure was as in D except GST-Chk1 was used instead of GST-TopBP1. F, after incubation with FLAG-
Claspin, MutS or MutL was pulled down using anti-MSH2 or anti-MLH1 bound to protein G beads (right
lanes). Negative controls included incubation of FLAG-Claspin with protein G beads alone or incubation of
FLAG-Claspin with protein G beads and MSH2 or MLH1 antibody in the absence of MutS or MutL (lanes
marked as -MSH2 or -MLH1). G, procedure was as in F except that incubation with Rad17-RFC was substituted
for FLAG-Claspin.
Interfacing Mismatch Repair with the ATR-Chk1 Pathway
5978 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 285 • NUMBER 8 • FEBRUARY 19, 2010
cell line backgrounds, although these activities were readily
detected in bulk chromatin samples used as input for immuno-
precipitation assay (Figs. 3 and 5).
The enrichment of checkpoint activities that we have
observed in anti-MLH1 and anti-MSH6 immunoprecipitates is
not a consequence of their nonspecific association with dam-
aged chromatin. Western analysis of bulk chromatin samples
used as input for immunoprecipitation assay demonstrated that
the levels of ATR, TopBP1, and Chk1 did not vary significantly
over the course of the experiment (supplemental Fig. S4). Chro-
matin-associated RPA did increase noticeably at 48 h post-
MNNG treatment, but this protein was not enriched in anti-
MLH1 or anti-MSH6 immunoprecipitates.
As noted above, different levels of basal association of
PCNA, ATR, TopBP1, and Chk1 were observed when chro-
matin samples derived from 293T L were precipitated
with anti-MSH6 as compared with TK6 chromatin samples
precipitated with anti-MLH1. To address this difference,
fragmented chromatin from TK6 cells were precipitated
using anti-MSH6. As shown in supplemental Fig. S3, the
results obtained were essentially identical to those observed
when 293T L cell chromatin was precipitated with anti-
MSH6 (Fig. 3), indicating that this effect is cell line-indepen-
dent. This finding suggests that the basal association differ-
ences observed in these experiments may be due to
precipitation of different chromatin subpopulations by anti-
MSH6 and anti-MLH1 antibodies.
DISCUSSION
The nature of the DNA damage signaling events triggered by
MutS andMutL are uncertain, although the consensus view
has implicated downstream involvement of the ATR-Chk1
pathway in mismatch repair-dependent responses to SN1 DNA
methylators. To better understand the interplay between these
two pathways, we have systematically examined interactions of
MutS and MutL with seven components of the ATR-Chk1
system, including ATR, Chk1, Rad17-RFC, 9-1-1, RPA,
TopBP1, and Claspin. Co-immunoprecipitation in nuclear
extracts indicated MutS interaction with ATR, TopBP1,
Claspin, and Chk1 and interaction of MutL with TopBP1 and
Claspin.AlthoughpurifiedMSH2has beenpreviously shown to
interact directly with ATR (29), our experiments extend this
finding to the functional MSH2MSH6 (MutS) form of the
protein. We have also demonstrated that MutS is capable of
FIGURE 3. Modified ChIP assay using 293T L and 293T L cells. Immu-
noprecipitation of micrococcal nuclease-digested formaldehyde-cross-
linked chromatin samples with anti-MSH6 was performed as described under
“Experimental Procedures.” After cross-link reversal, the samples were
resolved by electrophoresis on SDS gels, which were probed by Western blot
for proteins indicated on the left side of the figure. Negative controls included
incubation of chromatin samples with protein G beads (Beads only) or incu-
bation with protein G beads and mouse IgG (Mouse IgG). In each panel, the
numbers above the right six lanes indicate the time after MNNG exposure in
hours. Zero time samples were removed immediately prior to MMNG addi-
tion. Input (1/20) indicates that 5% of the zero time chromatin sample was
loaded.
FIGURE 4. Quantification of protein bands for modified ChIP assay using
293T L and 293T L cells. Band intensities of MSH6, histone H3, MLH1,
PCNA, ATR, TopBP1, and Chk1 at 0 –72 h post MNNG treatment were quanti-
fied using Image J (National Institutes of Health) and for each time sample
normalized to the corresponding histone H3 signal. The relative intensity was
then calculated by dividing the normalized intensity at each time by the zero
time sample on the same gel. The results from triplicate experiments are
expressed as the means  S.D. The values that differ significantly from zero
time relative intensities are indicated with asterisks (p  0.05, two-sample t
test). Quantification of results obtained with 293T L and 293T L chro-
matin samples are shown in A and B, respectively.
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direct interaction with Chk1 and TopBP1 and that MutL
interacts directly with TopBP1. We were unable to detect
MutS-Claspin andMutL-Claspin interactions using purified
components. Mismatch repair protein-Claspin interactions
that occur in nuclear extracts may therefore be indirect or
depend onpost-translationalmodification(s) thatwere not rep-
resented in the purified recombinant proteins used for this
study. These findings confirm and extend the results of others
(29, 41, 49–51), indicating the existence of a complex interac-
tion network involvingMutS, MutL, and components of the
ATR checkpoint pathway. Although RPA, Rad17-RFC, and
9-1-1 have also been implicated in ATR-dependent checkpoint
activation (36, 52), we were unable to detect interactions of
MutS or MutL with these activities by immunological assay
either in extracts or by use of purified components.
The significance of the interactions observed with purified
proteins was substantiated in formaldehyde-cross-linked chro-
matin fractions obtained fromMNNG-treated cells. Precipita-
tion of chromatin fragments with anti-MSH6 or anti-MLH1
resulted in enrichment for ATR, Chk1, and TopBP1, as well as
PCNA. Enrichment in this manner was dependent on prior
treatment with MNNG and functionality of MLH1 and MSH6
(Figs. 3–5), which are required for G2 checkpoint activation in
response to SN1DNAmethylators. Because the chromatin frag-
ments used in our experiments were relatively small (weight
average size, 400 bp; mode, 200 bp), the enrichment of sev-
eral activities may indicate MutS- and MutL-dependent
assembly of a large multi-protein complex during the course of
the damage response. Interestingly, recruitment of MutS and
MutL to MNNG-damaged chromatin precedes the recruit-
ment of PCNA, ATR, Chk1, and TopBP1, but neither the basis
nor the implications of this temporal effect are clear. Surpris-
ingly, enrichment of RPA, Rad17, Rad9, or Claspin, all of which
have been implicated in ATR-dependent checkpoint events,
was not observed in theMNNG-damaged chromatin subpopu-
lations that were selected by precipitation with anti-MSH6 or
anti-MLH1. There are several possible explanations for this
finding. Although the presence of these proteins was readily
demonstrable in the input chromatin samples, it is possible that
fraction recruited to the vicinity of MutS/MutL-chromatin
complexes was simply too small to be detected by the Western
blot methods we have used. This possibility is consistent with
previous suggestions that DNA-bound RPA and 9-1-1 play
important roles in the recruitment of ATRATRIP and TopBP1
to single-stranded DNA gaps (53–55).
A second possibility is suggested by the ability of MutS to
interact directly with ATR and TopBP1, and MutL with
FIGURE 5. Modified ChIP assay using TK6 and MT1 cells. A, MLH1 antibody
was used to immunoprecipitate MutL. The assay was done as in Fig. 3.
B, quantification of protein bands for the modified ChIP assay using TK6 and
MT cells. The band intensity of MutL and MSH2 at 0 –72 h post MNNG treat-
ment was quantified and analyzed as for Fig. 4.
FIGURE 6. MutS and MutL as a scaffold for recruitment of checkpoint
proteins. Based on the results of this study and previous findings of others
(29, 41, 49, 61), we suggest that the MutSMutL complex with a DNA lesion
may serve as a scaffold for recruitment of components of the ATR-Chk1
pathway.
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TopBP1. Such interactions could provide an alternate pathway
for recruitment of ATR and TopBP1 to DNA lesions in a man-
ner that does not require RPA or 9-1-1 (Fig. 6). Such a mecha-
nism would also account for our inability to detect chromatin
enrichment of RPA, Rad17-RFC, or 9-1-1 in anti-MSH6or anti-
MLH1 immunoprecipitates. Inasmuch as TopBP1 has been
shown to activate ATR (39, 40, 54–59), co-recruitment of these
two activities to DNA lesions by MutS and MutL might be
sufficient to trigger ATR-dependent checkpoint activation.
Although such amechanism could be viewed as consistent with
the direct signalingmodel described above, our experiments do
not rule out the futile cycling model. For example, if the mis-
match repair DNA synthesis step is fast relative to excision
triggered by a MeG lesion, then the steady-state level of the
RPA-bound gapped excision intermediate could be very low.
Indeed and as noted above, there is excellent evidence implicat-
ing Exo1, the primary hydrolytic activity involved in eukaryotic
mismatch repair (60), in the cellular response to SN1 DNA
methylator damage (34). Unfortunately we have been unable to
test for the presence of this activity in chromatin immunopre-
cipitates because the levels of this activity are so low that it
cannot be detected immunologically in cell extracts. The idea
that direct recruitment of ATR and TopBP1 by MutS and
MutL may provide an alternate mechanism for ATR activa-
tion makes several testable predictions, and we are pursuing
these possibilities.
Acknowledgments—We thank Ravi Iyer, Leonid Dzantiv, and Farid
Kadyrov for purified proteins and Elisabeth Penland for cell culture.
REFERENCES
1. Iyer, R. R., Pluciennik, A., Burdett, V., andModrich, P. L. (2006)Chem. Rev.
106, 302–323
2. Jiricny, J. (2006) Nat. Rev. Mol. Cell Biol. 7, 335–346
3. Li, G. M. (2008) Cell Res. 18, 85–98
4. Hsieh, P., and Yamane, K. (2008)Mech. Aging Dev. 129, 391–407
5. Holmes, J., Jr., Clark, S., and Modrich, P. (1990) Proc. Natl. Acad. Sci.
U.S.A. 87, 5837–5841
6. Thomas, D. C., Roberts, J. D., and Kunkel, T. A. (1991) J. Biol. Chem. 266,
3744–3751
7. Iams, K., Larson, E. D., and Drummond, J. T. (2002) J. Biol. Chem. 277,
30805–30814
8. Genschel, J., and Modrich, P. (2003)Mol. Cell 12, 1077–1086
9. Dzantiev, L., Constantin, N., Genschel, J., Iyer, R. R., Burgers, P. M., and
Modrich, P. (2004)Mol. Cell 15, 31–41
10. Zhang, Y., Yuan, F., Presnell, S. R., Tian, K., Gao, Y., Tomkinson, A. E., Gu,
L., and Li, G. M. (2005) Cell 122, 693–705
11. Constantin, N., Dzantiev, L., Kadyrov, F. A., andModrich, P. (2005) J. Biol.
Chem. 280, 39752–39761
12. Kadyrov, F. A., Dzantiev, L., Constantin, N., and Modrich, P. (2006) Cell
126, 297–308
13. Kadyrov, F. A., Holmes, S. F., Arana, M. E., Lukianova, O. A., O’Donnell,
M., Kunkel, T. A., andModrich, P. (2007) J. Biol. Chem. 282, 37181–37190
14. Longley, M. J., Pierce, A. J., and Modrich, P. (1997) J. Biol. Chem. 272,
10917–10921
15. Ramilo, C., Gu, L., Guo, S., Zhang, X., Patrick, S. M., Turchi, J. J., and Li,
G. M. (2002)Mol. Cell. Biol. 22, 2037–2046
16. Stojic, L., Brun, R., and Jiricny, J. (2004) DNA Repair 3, 1091–1101
17. O’Brien, V., and Brown, R. (2006) Carcinogenesis 27, 682–692
18. Kaina, B., Christmann, M., Naumann, S., and Roos, W. P. (2007) DNA
Repair 6, 1079–1099
19. Goldmacher, V. S., Cuzick, R. A., Jr., andThilly,W.G. (1986) J. Biol. Chem.
261, 12462–12471
20. Karran, P., and Bignami, M. (1992) Nucleic Acids Res. 20, 2933–2940
21. Haracska, L., Prakash, S., and Prakash, L. (2000) Mol. Cell. Biol. 20,
8001–8007
22. Duckett, D. R., Bronstein, S. M., Taya, Y., and Modrich, P. (1999) Proc.
Natl. Acad. Sci. U.S.A. 96, 12384–12388
23. Duckett, D. R., Drummond, J. T., Murchie, A. I., Reardon, J. T., Sancar, A.,
Lilley, D. M., and Modrich, P. (1996) Proc. Natl. Acad. Sci. U.S.A. 93,
6443–6447
24. York, S. J., and Modrich, P. (2006) J. Biol. Chem. 281, 22674–22683
25. Tominaga, Y., Tsuzuki, T., Shiraishi, A., Kawate, H., and Sekiguchi, M.
(1997) Carcinogenesis 18, 889–896
26. Stojic, L., Mojas, N., Cejka, P., Di Pietro, M., Ferrari, S., Marra, G., and
Jiricny, J. (2004) Genes Dev. 18, 1331–1344
27. Beardsley, D. I., Kim, W. J., and Brown, K. D. (2005)Mol. Pharmacol. 68,
1049–1060
28. Yoshioka, K., Yoshioka, Y., and Hsieh, P. (2006)Mol. Cell 22, 501–510
29. Wang, Y., and Qin, J. (2003) Proc. Natl. Acad. Sci. U.S.A. 100,
15387–15392
30. Kat, A., Thilly, W. G., Fang, W. H., Longley, M. J., Li, G. M., andModrich,
P. (1993) Proc. Natl. Acad. Sci. U.S.A. 90, 6424–6428
31. Mojas, N., Lopes, M., and Jiricny, J. (2007) Genes Dev. 21, 3342–3355
32. Ceccotti, S., Aquilina, G., Macpherson, P., Yamada, M., Karran, P., and
Bignami, M. (1996) Curr. Biol. 6, 1528–1531
33. Schaetzlein, S., Kodandaramireddy, N. R., Ju, Z., Lechel, A., Stepczynska,
A., Lilli, D. R., Clark, A. B., Rudolph, C., Kuhnel, F.,Wei, K., Schlegelberger,
B., Schirmacher, P., Kunkel, T. A., Greenberg, R. A., Edelmann, W., and
Rudolph, K. L. (2007) Cell 130, 863–877
34. Klapacz, J., Meira, L. B., Luchetti, D. G., Calvo, J. A., Bronson, R. T., Edel-
mann, W., and Samson, L. D. (2009) Proc. Natl. Acad. Sci. U.S.A. 106,
576–581
35. Yang, G., Scherer, S. J., Shell, S. S., Yang, K., Kim, M., Lipkin, M., Kucher-
lapati, R., Kolodner, R. D., and Edelmann, W. (2004) Cancer Cell 6,
139–150
36. Sancar, A., Lindsey-Boltz, L. A., Unsal-Kaçmaz, K., and Linn, S. (2004)
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